Please login to the form below
Inlyta
This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer
Bavencio (avelumab), in combination with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), has been recommended as a first-line treatment for adult patients with advanced renal cell carcinoma (RCC) – the most ... The recommendation was based on
Latest news
-
BMS unveils long-term results for Opdivo in kidney cancer
RCC. BMS is facing increasing competition in kidney cancer, however, from the likes of other combination regimens such as Merck &Co/Pfizer’s Keytruda plus Inlyta and Pfizer/Merck KGaA’s ... Merck’s drug is also already widely prescribed by
-
NICE turns down Keytruda/Inlyta combo for kidney cancer
Cost-effectiveness agency says the long-term benefit is uncertain. NICE has said that the recently-approved combination of Merck &Co/MSD’s Keytruda with Pfizer’s Inlyta shouldn’t be ... The EU approval was based on the phase 3 KEYNOTE-426 trial,
-
Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer
Bavencio is also approved for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel cell carcinoma, and in combination with tyrosine kinase inhibitor Inlyta (axitinib) as
-
Aveo’s tivozanib is knocked back by FDA once again
inhibitors and VEGF inhibitors – in particular Pfizer’s VEGF inhibitor Inlyta (axitinib) – emerge as a strong therapeutic option.
-
Pfizer raises forecast following growth of biopharma business
Inlyta (axitinib) has also seen its revenues increase 98% to $139m, thanks to recent FDA approvals for the comination of the drug with Bavencio (avelumab) and Keytruda (pembrolizumab).
More from news
Approximately 7 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
The handover: Pfizer reshapes itself for a new era
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in
-
Cancer immunotherapy: What's on the horizon?
They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Mirna hires former Pfizer director as CMO
Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
A stumble, but not a fall – what’s next for Opdivo?
Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower
-
Oncology drugs under AMNOG
A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- Boehringer/Lilly's Jardiance hits the mark in pivotal heart failure trial
- Roche’s Tecentriq combo scores FDA approval for melanoma
- AstraZeneca escapes pandemic impact as new drugs bolster revenues
- Roche’s Actemra fails in late-stage severe COVID-19 study
- Live Webinar: Examining the Interface Between Healthcare & Society
- Novavax reports promising phase 1 results for coronavirus vaccine
- Merck enters agreement with Hanmi for investigational NASH drug
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Virtual Engagement At Porterhouse: Reflections on the past few months
- July 2020: diversity and inclusion in clinical trials round-up
PMHub
Nobull Communications
Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- ...
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
